Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Sponsor: Sundance Biosciences, Inc.
Summary
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
Official title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-10
Completion Date
2027-07
Last Updated
2026-09-25
Healthy Volunteers
No
Conditions
Interventions
SUN-627
SUN-627, a once daily, orally administered, immediate release tablet
Placebo
Orally-administered matched placebo
Locations (3)
Local Institution - Site 102
Atlanta, Georgia, United States
Local Institution - Site 101
Raleigh, North Carolina, United States
Local Institution - Site 104
Columbus, Ohio, United States